Trial · NCT02354352

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

NCT02354352, Phase 3, Completed, Ohio State University; results first posted 2019-09-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy. Trials, record NCT02354352. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02354352

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
NCT number: NCT02354352
Status: Completed
Phases: Phase 3
Enrollment: 52 participants, actual
Lead sponsor: Ohio State University
Conditions: Duchenne Muscular Dystrophy
Interventions: Eplerenone, Spironolactone
First posted: 2015-02-03
Last updated: 2019-10-07
Results first posted: 2019-09-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Left Ventricular Strain	12 months	a sensitive measure of heart muscle function

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Left Ventricular Strain	12 months	One patient in the spironolactone group did not receive a follow-up MRI.	Percent change in circumference	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Left Ventricular Strain	Eplerenone		0.2	Inter-Quartile Range -0.2 to 0.7	Percent change in circumference
Left Ventricular Strain	Spironolactone		0.4	Inter-Quartile Range -0.4 to 1.0	Percent change in circumference

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Eplerenone	26
Overall Study	STARTED	Spironolactone	26
Overall Study	2 Weeks	Eplerenone	26
Overall Study	2 Weeks	Spironolactone	25
Overall Study	1 Month	Eplerenone	24
Overall Study	1 Month	Spironolactone	23
Overall Study	2 Months	Eplerenone	24
Overall Study	2 Months	Spironolactone	22
Overall Study	3 Months	Eplerenone	25
Overall Study	3 Months	Spironolactone	23

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Rash	Skin and subcutaneous tissue disorders	Eplerenone	1	26	1
other	Rash	Skin and subcutaneous tissue disorders	Spironolactone	0	26	0
other	Nausea	Gastrointestinal disorders	Eplerenone	0	26	0
other	Nausea	Gastrointestinal disorders	Spironolactone	2	26	2
other	Gynecomastia	Endocrine disorders	Eplerenone	0	26	0
other	Gynecomastia	Endocrine disorders	Spironolactone	1	26	1
other	Nephrolithiasis	Renal and urinary disorders	Eplerenone	1	26	1
other	Nephrolithiasis	Renal and urinary disorders	Spironolactone	0	26	0
serious	Accidental Drowning	Injury, poisoning and procedural complications	Eplerenone	1	26	1
serious	Accidental Drowning	Injury, poisoning and procedural complications	Spironolactone	0	26	0

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Eplerenone	2	26
Total, all-cause mortality	Spironolactone	0	26
Total, other adverse events	Eplerenone	2	26
Total, other adverse events	Spironolactone	3	26
Total, serious adverse events	Eplerenone	3	26
Total, serious adverse events	Spironolactone	2	26

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
31549577	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Eplerenone vs Spironolactone: deaths from any cause	Trial comparisons
Eplerenone vs Spironolactone: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02354352

GET https://conductscience.org/api/trials/v1/NCT02354352/registered

API reference For AI assistants